| アブストラクト | BACKGROUND: Data on the clinical burden of eosinophilic granulomatosis with polyangiitis (EGPA) are limited. OBJECTIVE: We sought to evaluate the epidemiology and clinical burden of EGPA in England using real-world evidence. METHODS: Patients diagnosed with EGPA between January 1, 2006, and February 28, 2019, who had >/=1 year of data before diagnosis (index date) were identified using the Clinical Practice Research Datalink Aurum database. Epidemiology, diagnosis, mortality, treatment, and clinical outcomes were assessed. RESULTS: The incident and prevalent EGPA cohorts comprised 486 and 729 patients, respectively. The overall incidence and prevalence of EGPA were 3.04 (95% CI: 2.77-3.32) cases per million person-years and 2.7 (95% CI: 2.5-2.9) cases per 100,000 persons, respectively. Overall, 76.3% and 26.1% of patients had a Five Factor Score of 0 on the 1996 and 2009 versions. In the incident cohort (mean age 57.9 +/- 15.2 years), most patients (97.1%) had >/=1 comorbidity; 79.8% had asthma coded. The median time from first major manifestation to EGPA diagnosis was 44.0 (Q1-Q3: 20.0-56.0) months. The death rate was 37.1 per 1000 person-years (95% CI: 30.1-45.2); the standardized mortality ratio for all-cause deaths was 2.3 (95% CI: 1.9-2.8). The 5-year survival rate was 82.3% (95% CI: 78.1%-85.7%). Most patients (86.2%) received oral glucocorticoids, of whom 27.0% successfully tapered. Six months post index date, 26.1% of patients had a new EGPA manifestation. CONCLUSION: This study emphasizes the substantial clinical burden and reliance on glucocorticoids in EGPA, highlighting the need for improved diagnosis of this disorder. |
|---|
| ジャーナル名 | The journal of allergy and clinical immunology. Global |
|---|
| Pubmed追加日 | 2026/7/6 |
|---|
| 投稿者 | Siddiqui, Salman; Ding, Bo; Dolin, Paul; Edmonds, Chris; Jain, Priya; Rowell, Jennifer; Westerink, Lotte; Lacetera, Alessandra; Suarez-Sanchez, Pablo; Ariti, Cono; Podmore, Belene; Kitchin Velarde, Alvaro; Chen, Stephanie Y |
|---|
| 組織名 | National Heart and Lung Institute, National Institute for Health and Care;Research Imperial Biomedical Research Centre, Imperial College London.;BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Molndal, Sweden.;BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom.;Market Access and Pricing, AstraZeneca, Gaithersburg, Md.;Health Economics and Payer Evidence, AstraZeneca, Cambridge, United Kingdom.;OXON Epidemiology, Madrid, Spain.;BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Md. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/42405355/ |
|---|
